SCHEMBL208097

SCHEMBL208097

O=C(O)c1cccc(-c2ccccc2)n1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.64
ALOX15 P16050 1/20 0.64
TSHR P16473 1/20 0.64
ACMSD Q8TDX5 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
MEN1 O00255 1/20 0.60
RAB9A P51151 1/20 0.60
KMT2A Q03164 1/20 0.60
KAT6A Q92794 2/20 0.54
ECE1 P42892 1/20 0.53
HSD17B14 Q9BPX1 1/20 0.53
KMO O15229 1/20 0.52
MCL1 Q07820 2/20 0.51
CNR2 P34972 3/20 0.50
ALDH1A1 P00352 1/20 0.50
ASIC3 Q9UHC3 1/20 0.50
CNR1 P21554 1/20 0.49
ERN1 O75460 1/20 0.49
MGAM O43451 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29133274 0.98 KDM4E (0.61) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL3207980 0.96 KDM4E (0.59) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL5109866 0.88 HSD17B14 (0.60) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL70765 0.87 KDM4E (0.76) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL29357675 0.87 KDM4E (0.76) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL1944293 0.86 KDM4E (0.57) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL31301301 0.85 CNR2 (0.56) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL1137226 0.85 HSD17B14 (0.57) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL30614607 0.85 SMN1; SMN2 (0.56) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL30367705 0.85 HSD17B14 (0.57) KDM4EALOX15TSHRACMSDTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111440174-B Pyridine amide compound and preparation method and application thereof 广州医科大学 2021-07-09 CN claimed
US-20150299143-A1 SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2015-10-22 US claimed
EP-2925746-A1 SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS F. Hoffmann-La Roche AG (CH) 2015-10-07 EP claimed
CN-104968657-A Substituted triazole and imidazole compounds HOFFMANN LA ROCHE 2015-10-07 CN claimed
WO-2014086663-A1 SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2014-06-12 WO claimed
US-7662839-B2 EP2 receptor agonists ASTERAND UK LIMITED (GB) 2010-02-16 US claimed
EP-0034349-B1 NOVEL PYRIDINECARBOXAMIDE DERIVATIVES, A PROCESS FOR THE PREPARATION THEREOF, THE USE OF SAID DERIVATIVES AND A PHARMACEUTICAL COMPOSITION CONTAINING SAME Tanabe Seiyaku Co., Ltd. (JP) 1983-12-14 EP claimed
EP-0034349-A2 Novel pyridinecarboxamide derivatives, a process for the preparation thereof, the use of said derivatives and a pharmaceutical composition containing same Tanabe Seiyaku Co., Ltd. (JP) 1981-08-26 EP claimed
JP-55000307-A None JP disclosed
WO-2026107377-A1 PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL KARANICOLAS JOHN (US) 2026-05-21 WO disclosed
US-12570675-B2 Boronic acid compounds LG CHEM, LTD. (KR) 2026-03-10 US disclosed
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-11-13 US disclosed
US-12065428-B2 Anti-viral compounds ALIGOS THERAPEUTICS, INC. (US) 2024-08-20 US disclosed
US-20240101579-A1 BORONIC ACID COMPOUNDS LG CHEM, LTD. (KR) 2024-03-28 US disclosed
EP-0034349-B1 NOVEL PYRIDINECARBOXAMIDE DERIVATIVES, A PROCESS FOR THE PREPARATION THEREOF, THE USE OF SAID DERIVATIVES AND A PHARMACEUTICAL COMPOSITION CONTAINING SAME Tanabe Seiyaku Co., Ltd. (JP) 1983-12-14 EP disclosed
US-4332809-A ANTIALLERGENS TANABE SEIYAKU CO., LTD. (JP) 1982-06-01 US disclosed
EP-0034349-A2 Novel pyridinecarboxamide derivatives, a process for the preparation thereof, the use of said derivatives and a pharmaceutical composition containing same Tanabe Seiyaku Co., Ltd. (JP) 1981-08-26 EP disclosed
US-4259527-A OXIDATION OF SECONDARY ALCOHOLS TO KETONES WITH HYDROGEN PEROXIDE ALLIED CHEMICAL CORPORATION (US) 1981-03-31 US disclosed
JP-S55307-A PREPARATION OF 6-PHENYL-PICOLINIC ACID IDEMITSU KOSAN CO LTD 1980-01-05 JP disclosed
US-4171313-A OF ALICYCLIC KETONES TO LACTONES, W-HYDROXY ACIDS AND ESTERS USING HYDROGEN PEROXIDE AS AN OXIDIZING AGENT ALLIED CHEMICAL CORPORATION (US) 1979-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570675-B2 Boronic acid compounds PSMB6, PSMB3, PSMB2 KDM4E 3458/4885ALOX15 2564/4885TSHR 1670/4885
US-20150299143-A1 SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS HDAC7, PSMB7, IKZF3 KDM4E 865/4885ALOX15 3352/4885TSHR 3057/4885
US-12065428-B2 Anti-viral compounds EIF2AK2, ZC3HAV1, HAVCR2 KDM4E 3205/4885ALOX15 3208/4885TSHR 4775/4885
US-20240101579-A1 BORONIC ACID COMPOUNDS PSMB11, PSMB1, BACH1 KDM4E 2004/4885ALOX15 2587/4885TSHR 4034/4885
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C5, C1S, C9 KDM4E 4647/4885ALOX15 148/4885TSHR 3056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.